Dowling & Yahnke LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 25.7% during the second quarter, Holdings Channel reports. The institutional investor owned 23,520 shares of the medical device company’s stock after buying an additional 4,809 shares during the period. Dowling & Yahnke LLC’s holdings in DexCom were worth $1,720,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in DXCM. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of DexCom during the first quarter worth approximately $136,000. IFP Advisors Inc raised its position in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock worth $158,000 after buying an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new position in shares of DexCom during the first quarter worth approximately $164,000. Mn Services Vermogensbeheer B.V. raised its position in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock worth $179,000 after buying an additional 83 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of DexCom by 475.0% in the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock worth $195,000 after buying an additional 1,900 shares during the last quarter.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at 71.62 on Tuesday. The stock has a 50 day moving average price of $70.96 and a 200 day moving average price of $75.04. DexCom, Inc. has a 1-year low of $57.68 and a 1-year high of $96.38. The company’s market capitalization is $6.20 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The business’s revenue was up 24.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.24) earnings per share. On average, equities analysts anticipate that DexCom, Inc. will post ($0.77) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “DexCom, Inc. (DXCM) Shares Bought by Dowling & Yahnke LLC” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/15/dexcom-inc-dxcm-shares-bought-by-dowling-yahnke-llc.html.

A number of equities analysts recently commented on the company. TheStreet raised DexCom from a “d” rating to a “c-” rating in a research note on Wednesday, August 2nd. BidaskClub raised DexCom from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 9th. B. Riley reissued a “buy” rating and set a $95.00 price target on shares of DexCom in a research note on Sunday, May 7th. BMO Capital Markets reissued an “outperform” rating and set a $90.00 price target (down from $105.00) on shares of DexCom in a research note on Wednesday, August 2nd. Finally, Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus target price of $87.00.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Richard Doubleday sold 3,182 shares of the company’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $68.29, for a total value of $217,298.78. Following the completion of the transaction, the executive vice president now owns 72,395 shares in the company, valued at $4,943,854.55. The disclosure for this sale can be found here. Insiders sold 36,375 shares of company stock valued at $2,549,351 over the last 90 days. Company insiders own 1.70% of the company’s stock.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.